logo

For the Inventor, By the Inventor

Norristown, PA, United States of America

Martin Karl Russel Burnham

This inventor holds 42 USPTO granted patents, primarily in Prokaryotic Genetics. Top assignees: Smithkline Beecham Corporation, Affinium Pharmaceuticals, Inc., Other. Active years: 2001-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin Karl Russel Burnham. Retrieved from https://idiyas.com/inventor/martin-karl-russel-burnham

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 42

% Patents Active = 97.6

Average Co-Inventor Count = 4.9

ph-index = 5

Forward Citations = 123(Granted Patents)


Location History:

  • Barto, PA (US) (2001 - 2002)
  • King of Prussia, PA (US) (2002)
  • Norristown, PA (US) (2001 - 2003)
  • Norristwon, PA (US) (2007)

Company Filing History:

goldMedal24 out of 2,198 
 
Smithkline Beecham Corporation
 patents
silverMedal1 out of 33 
 
Affinium Pharmaceuticals, Inc.
 patents
bronzeMedal17 out of 834,601 
Other
 patents

Years Active: 2001-2007

Loading Chart...
Areas of Expertise:
Polynucleotide
Fibronectin Binding
ATP Binding Protein
Prokaryotic Polypeptides
Glutamine Transport
Nucleic Acid
Staphylococcus Aureus
Streptococcus Pneumoniae
Histidinol Dehydrogenase
Glycogen Phosphorylase
3-Dehydroquinate Synthase
Nucleotide Pyrophosphorylase
42 patents (USPTO):Explore Patents
1. 7250285 - [object Object] (2007-07-31),
2. 6524813 - Polynucleotide encoding spo0J1 of Staphylococcus aureus (2003-02-25),
3. 6465621 - Compounds (2002-10-15),
4. 6461614 - Fibronectin binding proteins (2002-10-08),
5. 6447773 - Member of ATP dependent protease family, clpL (2002-09-10),
6. 6399343 - inFB (2002-06-04),
7. 6365159 - Spo-rel (2002-04-02),
8. 6358704 - M protein (2002-03-19),
9. 6348584 - Fibronectin binding protein compounds (2002-02-19),
10. 6348582 - Prokaryotic polynucleotides polypeptides and their uses (2002-02-19),
11. 6346608 - MecB (2002-02-12),
12. 6346392 - Polynucleotides encoding a novel glutamine transport ATP-binding protein (2002-02-12),
13. 6344540 - PAI (2002-02-05),
14. 6340564 - yhxB (2002-01-22),
15. 6335433 - nrdD (2002-01-01),

Title: Martin Karl Russel Burnham: Innovator in Antibacterial Compound Research

Introduction

Martin Karl Russel Burnham is an accomplished inventor based in Norristown, PA, holding an impressive portfolio of 42 patents. His contributions to the field of biotechnology, particularly in the development of polypeptides and their applications in screening antibacterial compounds, have made significant impacts in medical research and pharmaceutical advancements.

Latest Patents

Among his latest patents, Burnham has developed novel polypeptides and polynucleotides that facilitate the production of these polypeptides via recombinant techniques. These inventions provide valuable methods for utilizing such polypeptides in screening for antibacterial compounds. Additionally, he has focused on spo0J1 polypeptides and polynucleotides encoding this specific protein of Staphylococcus aureus, further enhancing the methods available for antibacterial compound screening.

Career Highlights

Burnham's career has been marked by his affiliation with prominent companies in the biotechnology sector, including SmithKline Beecham Corporation. His work in these environments has allowed him to leverage his expertise to innovate in the field of molecular biology and contribute to advancements in healthcare.

Collaborations

Throughout his career, Burnham has collaborated with notable professionals such as John Edward Hodgson and Patrick Vernon Warren. These partnerships have enriched his endeavors, fostering a collaborative spirit and shared expertise in their research initiatives.

Conclusion

Martin Karl Russel Burnham remains a noteworthy figure in the realm of antibacterial research and biotechnology. With an extensive patent portfolio and a history of meaningful collaborations, his contributions continue to influence the development of new therapeutics and methods in medical science. His ongoing commitment to innovation ensures that his work will remain significant in the pursuit of effective antibacterial solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…